Literature DB >> 11980011

[T1 bladder tumors: value of a second endoscopic resection].

Jérôme Rigaud1, Georges Karam, Guillaume Braud, Pascal Glemain, Jean-Marie Buzelin, Olivier Bouchot.   

Abstract

OBJECTIVE: To quantify the percentage of residual tumour following systematic second endoscopic resection of pT1 bladder tumours before starting treatment with intravesical instillations and to definitively exclude muscle invasion.
MATERIAL AND METHODS: From January 1995 to December 1999, 52 patients with a first diagnosis of pT1 bladder tumour underwent a second endoscopic resection 3 to 5 weeks later. Nine surgeons, 5 seniors and 4 juniors, managed these patients and the initial resection was considered to be complete in every case. The second resection consisted of resection of the initial tumour bed and distant biopsies either directed to zones of suspicious CIS zones or quadrant biopsies in the case of optically healthy mucosa.
RESULTS: Of the 52 included patients, 19 (36.5%) had residual disease on the second endoscopic resection. Pathological staging was: pT0 = 63.5% (33 patients), pTa = 11.5% (6 patients), pTis = 3.85% (2 patients), pT1 = 17.3% (9 patients), > or = pT2 = 3.85% (2 patients). Residual tumour tissue was revealed at the resection site in 84.2% of cases and in another site in 15.8% of cases. Residual tumour was significantly more frequent in the case of multifocal tumour than in the case of solitary tumour (57.9% vs 24.23%), and when managed by a junior surgeon compared to a senior surgeon (53.8% vs 30.8%).
CONCLUSION: This second endoscopic procedure appears to be essential to ensure the absence of residual tumour before starting conservative treatment for pT1 bladder tumours.

Entities:  

Mesh:

Year:  2002        PMID: 11980011

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  5 in total

1.  The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.

Authors:  Askin Eroglu; Rahmi Gokhan Ekin; Gokhan Koc; Rauf Taner Divrik
Journal:  Int J Clin Oncol       Date:  2019-11-23       Impact factor: 3.402

Review 2.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

3.  Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.

Authors:  Guido Dalbagni; Kinjal Vora; Matthew Kaag; Angel Cronin; Bernard Bochner; S Machele Donat; Harry W Herr
Journal:  Eur Urol       Date:  2009-07-17       Impact factor: 20.096

4.  Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.

Authors:  Yusuke Kimura; Masashi Honda; Shuichi Morizane; Katsuya Hikita; Tadahiro Isoyama; Koji Ono; Tsutomu Koumi; Chihiro Takahashi; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2019-06-20       Impact factor: 1.641

5.  The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer.

Authors:  Nikhil Vasdev; Jose Dominguez-Escrig; Edgar Paez; Mark I Johnson; Garrett C Durkan; Andrew C Thorpe
Journal:  Ecancermedicalscience       Date:  2012-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.